ClinicalTrials.gg
RecruitingNCT04496349Updated Nov 4, 2025

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

A Phase 2 interventional study of APG-115 and APG-2575 in T-Prolymphocytic Leukemia and Non-Hodgkins Lymphoma, sponsored by Ascentage Pharma Group Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Leukemia, Prolymphocytic, T-Cell · United States.

Planned enrollment
4th of 23
78 · median 30
Started
2021
with 2 others
Phase 2
7 of 24
2 open now
Registered
14th of 24
by date
Lead sponsor
1 of 24
Ascentage Pharma Group Inc.

Among the 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 14th registered.

Leukemia, Prolymphocytic, T-Cell

30 studies on the registry are indexed under Leukemia, Prolymphocytic, T-Cell; 8 are open to participants now.

Browse Leukemia, Prolymphocytic, T-Cell studies →

Open to participants now

6 of the 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Leukemia, Prolymphocytic, T-Cell studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Leukemia, Prolymphocytic, T-Cell with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.

Read the detailed description

This is a phase IIa, open-label, multi-center, clinical trial of interfering the binding of MDM2 oncoprotein with the tumor suppressor P53 protein, leads to increased P53 and P21 protein expression and activates P53-mediated apoptosis. The hypothesis is that APG-115 monotherapy and in combination with APG-2575 will shows good safety and efficacy in patients with R/R T-PLL and NHL

03

Conditions studied

  • T-Prolymphocytic Leukemia
  • Non-Hodgkins Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old
  2. Patients with T-PLL who have active disease and have received at least one prior therapy; Patients with confirmed diagnosis of NHL, NHL Patients must be either relapsed, refractory, intolerant, or are considered ineligible for therapies known to provide clinical benefit;
  3. Patients must not have had chemotherapy or antibody therapy for 7 days prior to starting APG-115 and/or APG-2575. However, patients with rapidly proliferative disease may receive hydroxyurea or decadron until 24 hours prior to starting therapy on this protocol.
  4. (ANC) ≥ 500/mm˄3; ≥ 60 g/L; count ≥ 30,000/mm˄3
  5. Patients with adequate organ function;
  6. (ECOG) performance status ≤ 2;
  7. Patient must have the ability to understand the requirements of the study and signed . A signed informed consent by the patient or his/her legally authorized representative is required prior to their enrollment on the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patient previously treated with a murine double minute 2 (MDM2) inhibitor.
  2. Known active, uncontrolled central nervous system (CNS)
  3. Patients require graft versus host therapy, or require continued treatment with systemic agents (calcineurin inhibitors within 4 weeks prior to the first dose of study drug).
  4. Patients who have any conditions or illness that, according to the opinions of the Investigators or the medical monitor, would compromise patient safety or interfere with the evaluation of safety and efficacy to the study drug(s).
  5. Patients who have used strong CYP2C8 inhibitors, or moderate or strong inhibitors or inducers within of 14 days or 7 half-lives before the first administration of study drugs, whichever is longer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    APG-115 monotherapy part

    APG-115 will be given alone

    Drug: APG-115

  • Experimental
    APG-115 + APG-2575 combination dose escalation part

    APG-115 is given in combination with APG-2575

    Drug: APG-115 · Drug: APG-2575

  • Experimental
    APG-115 + APG-2575 combination dose expansion part

    APG-115 is given in combination with APG-2575

    Drug: APG-115 · Drug: APG-2575

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose of APG-115

    To evaluate the safety of APG-115 as a single agent

    Time frame: 21 days

  2. Maximum tolerated dose of APG-115+APG-2575

    To evaluate the maximum tolerated dose of APG-115 and APG-2575 in combination

    Time frame: 21 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for May 2026, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2020
First posted
Aug 3, 2020
StartActual
Jul 12, 2021
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2027
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04496349
Responsible party
Sponsor
First posted
Aug 3, 2020
Start date
Jul 12, 2021
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 4, 2025

Study contacts

Genevieve Frank
Contact
genevieve.frank@ascentage.com
301-802-3659
Jocelyn Budzynski
Contact
jocelyn.budzynski@ascentage.com
301-693-6952
Yifan Zhai, MD, PhD
study chair · Ascentage Pharma Group Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alrizomadlin

Start the discussion